Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo Nordisk's Wegovy pill for obesity.

Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout

Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s…

Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo Nordisk's Wegovy pill for obesity.